FDA Panel Backs REGN's Cholesterol Drug, SAGE Cheered Up, Keep Watch Over TXMD

Prothena Corp. plc (PRTA) has successfully dosed the first human in a phase I, single ascending dose study of its proprietary protein immunotherapy, PRX003, designed to enroll up to 40 subjects in the U.S. PRX003 is a monoclonal antibody targeting melanoma cell adhesion molecule (MCAM) for the poten...

Full description

Saved in:
Bibliographic Details
Published inRTTNews
Format Newspaper Article
LanguageEnglish
Published Williamsville Global Network Content Services LLC, DBA Noticias Financieras LLC 10.06.2015
Subjects
Acne
Clinical trials
Drug dosages
Medical treatment
Patients
Postpartum depression
Womens health
Online AccessGet full text

Cover

More Information
Summary:Prothena Corp. plc (PRTA) has successfully dosed the first human in a phase I, single ascending dose study of its proprietary protein immunotherapy, PRX003, designed to enroll up to 40 subjects in the U.S. PRX003 is a monoclonal antibody targeting melanoma cell adhesion molecule (MCAM) for the potential treatment of psoriasis and other inflammatory diseases. According to the exploratory trial results, all four patients rapidly achieved remission, as measured by the Hamilton Rating Scale for Depression, and also demonstrated consistent improvement as measured by the Clinical Global Impression-Improvement scale during the SAGE-547 treatment period.